

Research article

Open Access

Fibroblasts from patients with Diamond-Blackfan anaemia show abnormal expression of genes involved in protein synthesis, amino acid metabolism and cancer

Federica Avondo¹, Paola Roncaglia², Nicoletta Crescenzo³, Helena Krmac², Emanuela Garelli³, Marta Armiraglio¹, Carlotta Castagnoli⁴, Maria Francesca Campagnoli³, Ugo Ramenghi³, Stefano Gustincich², Claudio Santoro¹ and Irma Dianzani*¹

Address: ¹Department of Medical Sciences and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), Università del Piemonte Orientale, Novara, Italy, ²International School for Advanced Studies (SISSA/ISAS), Trieste, Italy, ³Department of Pediatric Sciences, Università di Torino, Torino, Italy and ⁴Azienda Ospedaliera CTO/CRF/Maria Adelaide, Torino, Italy

Email: Federica Avondo - avondo@med.unipmn.it; Paola Roncaglia - roncagli@sisssa.it; Nicoletta Crescenzo - nicoleta.crescenzo@unito.it; Helena Krmac - krmac@sisssa.it; Emanuela Garelli - emanuela.garelli@unito.it; Marta Armiraglio - armiral@med.unipmn.it; Carlotta Castagnoli - ccastagnoli@hotmail.com; Maria Francesca Campagnoli - mariafrancesca.campagnoli@unito.it; Ugo Ramenghi - ugo.ramenghi@unito.it; Stefano Gustincich - gustinci@sisssa.it; Claudio Santoro - csantoro@med.unipmn.it; Irma Dianzani* - irma.dianzani@med.unipmn.it

* Corresponding author

Published: 18 September 2009

Received: 19 January 2009

BMC Genomics 2009, 10:442 doi:10.1186/1471-2164-10-442

Accepted: 18 September 2009

This article is available from: <http://www.biomedcentral.com/1471-2164/10/442>

© 2009 Avondo et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Diamond-Blackfan anaemia (DBA) is a rare inherited red cell hypoplasia characterised by a defect in the maturation of erythroid progenitors and in some cases associated with malformations. Patients have an increased risk of solid tumors. Mutations have been found in several ribosomal protein (RP) genes, i.e. *RPS19*, *RPS24*, *RPS17*, *RPL5*, *RPL11*, *RPL35A*. Studies in haematopoietic progenitors from patients show that haplo-insufficiency of an RP impairs rRNA processing and ribosome biogenesis. DBA lymphocytes show reduced protein synthesis and fibroblasts display abnormal rRNA processing and impaired proliferation.

Results: To evaluate the involvement of non-haematopoietic tissues in DBA, we have analysed global gene expression in fibroblasts from DBA patients compared to healthy controls. Microarray expression profiling using Affymetrix GeneChip Human Genome U133A 2.0 Arrays revealed that 421 genes are differentially expressed in DBA patient fibroblasts. These genes include a large cluster of ribosomal proteins and factors involved in protein synthesis and amino acid metabolism, as well as genes associated to cell death, cancer and tissue development.

Conclusion: This analysis reports for the first time an abnormal gene expression profile in a non-haematopoietic cell type in DBA. These data support the hypothesis that DBA may be due to a defect in general or specific protein synthesis.

Background

Protein synthesis is essential to the survival and growth of cells. Ribosomes, the sites where translation occurs, therefore play a fundamental role in cell biology. In human cells, ribosome biogenesis occurs in the nucleolus: it requires the transcription of four ribosomal RNA (rRNA) species and their assembly with 79 ribosomal proteins (RPs) in order to produce the small (40S) and large (60S) ribosomal subunits. These subunits are independently exported to the cytoplasm and joined to obtain mature ribosomes [1].

Several inherited or acquired bone marrow failure syndromes are due to mutations in genes encoding proteins involved in ribosome biogenesis. They include Diamond-Blackfan anaemia (DBA, MIM#105650), Shwachman-Diamond syndrome (SDS, MIM#260400), dyskeratosis congenita (DC, MIM#127550, #305000, #224230) and 5q- syndrome (MIM#153550) [2,3]. DBA is an inherited erythroid hypoplasia which usually develops within the first year of life and is characterised by a severe normochromic macrocytic anaemia caused by a defect in the maturation of erythroid progenitors. Haematological signs include paucity of bone marrow progenitors, reticulocytopenia, elevated erythrocyte adenosine deaminase (eADA) activity and high levels of foetal haemoglobin. Patients are prone to develop malignancies and one third of them present congenital abnormalities [4,5]. Mutations causing DBA have been found so far in six RP genes, encoding both small and large subunit components: *RPS19* (in 25% of cases), *RPS24* (2%), *RPS17* (one case), *RPL35A* (2%), *RPL5* (9%) and *RPL11* (6.5%), overall accounting for about 50% of cases [6-10]. All patients are heterozygous with respect to mutations and haplo-insufficiency is thought to be responsible for the pathogenetic mechanism of the disease. The main hypothesis to explain DBA implies that a defect in ribosome biogenesis and protein synthesis would trigger apoptotic processes in erythroid progenitors. This is supported by several studies showing that mutations in RPs impair rRNA processing, both in CD34⁺ cells from DBA patients and in erythroid cells with knock-down of the known DBA genes [8-13]. Mutations in different genes impair different steps of rRNA maturation, but they all lead to the accumulation of rRNA precursors and to a reduction in mature ribosomes. Similar alterations have also been demonstrated in yeast and human cells deficient for other RPs, not yet found mutated in DBA [2,14,15]. However, the link between the haplo-insufficiency of an RP and the erythroid defect occurring in DBA has not been clarified yet.

DBA has been considered a disease that affects only erythroid progenitors and thus the prototype of a pure erythroid aplasia. However, several lines of evidence suggest that erythroid progenitors, though apparently more sensi-

tive to RP haplo-insufficiency than other cell types, are not the only cell type affected in DBA. Some patients evolve trilinear aplasia [16], showing that haematopoiesis in general can be affected, while the presence of congenital malformations demonstrates that some organogenetic processes are affected by DBA mutations. Moreover, patients show short statures well below their genetic potentials [5].

To gain a better insight into the biological processes and functions involved in the pathogenesis of DBA, we performed a global gene expression analysis of fibroblasts isolated from DBA patients carrying mutations in *RPS19*. Our data reveal for the first time the presence of abnormal gene expression in non-haematopoietic DBA cells. Protein synthesis, nucleotide and amino acid metabolism and apoptosis are the most affected biological processes.

Results

Gene expression profiling of cells from DBA patients

To identify genes associated with a defect of *RPS19*, a whole genome expression profiling study was performed using Affymetrix GeneChip Human Genome U133A 2.0 Arrays which allow the screening of 18,400 transcripts, including 14,500 well-characterised genes. We analysed the gene expression profiles of dermal fibroblasts isolated from four DBA patients carrying mutations in *RPS19*, in comparison to those obtained from six healthy individuals. Of the 22,227 probes present on the chip, 13,396 had Affymetrix "Present" detection calls and intensity values more than 100 in all arrays and have been used for data analysis. A list of 490 statistically significantly differentially expressed probes was generated, 215 of which are up-regulated and 275 down-regulated in DBA patients (see additional file 1: Genes differentially expressed in DBA patients identified by microarray profiling). These probes correspond to 421 differentially expressed genes (176 up-regulated and 245 down-regulated) in patients compared to controls.

We also evaluated whether the observed differences in gene expression may be due to a gender-dependent bias. The comparison between the array data of female to male individuals irrespective of the health status yielded a list of 33 differentially expressed probes (six up-regulated and 27 down-regulated in females), corresponding to genes mainly located on chromosomes X or Y (see additional file 2: Differentially expressed genes in females relative to males). Moreover, we identified only five differentially expressed genes in female DBA patients relative to male DBA patients (see additional file 3: Differentially expressed genes in female patients relative to male patients). These results rule out the presence of gender-dependent defects in DBA patients.

Microarray analysis was performed on samples from patients carrying two missense (p.Arg62Trp and p.Arg101His), one frameshift and one splice site mutations (c.58delG and c.1-1G>A) in *RPS19* (table 1). We did not identify any gene showing a statistically significant differential expression in patients with missense mutations compared to other mutation types, indicating that changes due to the specific nature of the mutational status were not found in our study.

Microarray analysis did not show any statistically significant difference in the mean expression of *RPS19* when the group of patients is compared to the group of controls. This is due to the fact that two patients carried missense mutations that are expressed similarly to controls. Inspection of the microarray data relative to each patient showed that patient 4 with the frameshift mutation c.del58G had reduced *RPS19* levels (fold change 0.68) as expected by activation of NMD [17,18]. A slightly reduced *RPS19* expression was found also in patient 3 carrying mutation c.1-1G>A (fold change 0.84). This was confirmed by qRT-PCR with a fold change of 0.76 as compared to five controls (data not shown). Mutation c.1-1G>A affects intron 1 acceptor splice site and is expected to cause exon 2 skipping. PCR using primers complementary to exon 1 (forward) and exon 4 (reverse) revealed the presence of two amplicons of 628 and 557 bp in patient 3 (figure 1a). Sequencing of PCR products confirmed that the smaller abnormal transcript lacks exon 2 which contains the canonical ATG (figure 1b). The first available ATG at position 96-98 in exon 3 is out-of-frame (nucleotide numbering uses the A of the ATG translation initiation start site as nucleotide 1): this transcript is expected to be degraded by NMD [17,18]. However, we cannot rule out that the use of the in-frame ATG at codon 75 in exon 4 would generate a short protein of 71 aminoacids. Either way, a loss of function effect is expected to occur by this mutation in agreement with the assumed haploinsufficiency theory of DBA pathogenesis.

Biological processes altered in DBA patients

In order to systematically detect impaired biological processes and molecular functions, we analysed the dataset of genes differentially expressed in patients relative to controls through the use of Ingenuity Pathways Analysis [19]. The analysis identified a statistically significant enrichment of genes that belong to the following pathways (table 2): aminoacyl-tRNA biosynthesis (*LARS*, *WARS*, *GARS*, *SARS*, *QARS*, *EPRS*), glycine, serine and threonine metabolism (*PSAT1*, *PHGDH*, *GARS*, *CTH*, *SARS*, *SHMT2*), death receptor signaling (*CASP9*, *NFKBIA*, *NFKBIE*, *APAF1*, *NFKB2*, *NFKB1*, *BIRC3*), role of PKR in interferon induction and antiviral response (*CASP9*, *NFKBIA*, *NFKBIE*, *APAF1*, *NFKB2*, *NFKB1*) and RAR activation (*SRC*, *PRMT2*, *RDH11*, *ADCY3*, *PRKACA*, *NFKB2*, *NFKB1*, *MAPKAPK2*, *RBP1*, *MMP1*, *PTEN*). In addition, analysis of the molecular function of the annotated genes revealed enrichment of gene clusters with roles in protein synthesis, including a large cluster of RP genes (*RPL22*, *RPL27A*, *RPL29*, *RPL31*, *RPL14*, *RPL18A*, *RPS3*, *RPL18*, *RPL13*, *RPL3*, *RPL34*, *RPS2*, *RPS12*, *RPL15*, *RPL28*), cell death, cellular development, lipid metabolism and molecular transport. Additionally, we identified clusters of genes belonging to the "Top Bio Functions" category of molecular and cellular functions (table 3) and diseases and disorders, which comprises cancer related genes, as well as genes involved in haematological, immunological, renal and skeletal disorders (table 4). Finally, we observed enriched clusters of genes related to the development and function of embryonic, skeletal and connective tissues (table 5).

Quantitative RT-PCR validation of microarray data

In order to corroborate the microarray gene expression results, we selected seven genes among those differentially expressed in DBA patients relative to controls. Real-time RT-PCR was performed on the same RNA samples used for microarray analysis. The expression of *AMPD3*, *CCND2*, *SOD2*, *TNFAIP3* (up-regulated in DBA patients) and

Table 1: Clinical characteristics of DBA patients

Patient	Gender	Mutation (RPS19)	Steroid Response	Follow-up	Congenital Abnormalities
1	M	p.Arg62Trp	R/ ^a	BMT/Rem ^e	yes
2	F	p.Arg101His	R ^b	TRT/Rem ^f	no
3	F	c.1-1G>A	NR ^{c, d}	BMT/Rem	no
4	M	c.del58G	R	SD ^g	no

^a R/I responsive and subsequent interruption of therapy

^b R responsive

^c this patient was transfusion dependent

^d NR non responsive

^e BMT/Rem remission after bone marrow transplant

^f TRT/Rem remission after treatment

^g SD steroid dependent




Figure 1
RPS19 expression in patient 3. a) RPS19 expression in patient 3 and controls is shown. Primers complementary to exon 1 (forward) and exon 4 (reverse) were used. Two PCR products are indicated in lane 1 at 628 and 557 bp. b) Sequencing of RPS19 in patient 3. Exon 2 is 71 nt long and the first three nucleotides represent the translation initiation start site (bold). The chromatogram shows deletion of exon 2 in c.1-1G>A allele compared to the wild-type sequence in patient 3.

Table 2: Ingenuity Pathways Analysis: Top canonical pathways.

Pathway	-Log(P-value*)	Ratio**	Molecules	N°
Aminoacyl-tRNA Biosynthesis	3.36E+00	7.14E-02	LARS, WARS, GARS, SARS, QARS, EPRS	6
Role of PKR in Interferon Induction and Antiviral Response	2.84E+00	1.28E-01	CASP9, NFKBIA, NFKBIE (includes EG:4794), APAF1, NFKB2, NFKBI	6
Death Receptor Signaling	2.73E+00	1.08E-01	CASP9, NFKBIA, NFKBIE (includes EG:4794), APAF1, NFKB2, NFKBI, BIRC3	7
Glycine, Serine and Threonine Metabolism	2.31E+00	4.17E-02	PSAT1, PHGDH, GARS, CTH, SARS, SHMT2	6
RAR Activation	2.28E+00	6.04E-02	SRC, PRMT2, RDH11, ADCY3, PRKACA, NFKB2, NFKBI, MAPKAPK2, RBPI, MMP1 (includes EG:4312), PTEN	11

*Fischer's exact test was used to calculate a p-value determining the probability that each canonical pathway assigned to that data set is due to chance alone.

**Number of genes from the dataset that map to the pathway divided by the total number of molecules that exist in the canonical pathway

COMP, WARS and ZIC1 (down-regulated in DBA patients) was tested. All genes were found to be differentially expressed in patients relative to controls and data are statistically significant (figure 2a). The correlation between qRT-PCR and microarray data is 0.7 (figure 2b), which corresponds to the value obtained in similar studies [20,21]. Figure 2c shows the comparison of fold changes from qRT-PCR and microarray analysis. Microarray data showed the same trend as qRT-PCR results for all

the examined genes in each sample, as represented in figure 3. These data overall indicate that the expression patterns detected by microarray analysis are in good agreement with those detected by qRT-PCR and validate our study.

Discussion

The most prominent feature in DBA is anaemia due to paucity of erythroid progenitors. However, other cellular

Table 3: Ingenuity Pathways Analysis: Top Bio Functions - Molecular and Cellular Functions

Category	P-value*	Molecules	N°
Protein Synthesis	3.67E-07 to 3.06E-02	MME, RPL22, UBE2H (includes EG:7328), RPL27A, LIF, RPL29, MMP14, RPL31, RPL14, IDE, NFKBI, EIF4EBPI, CASP9, TRHDE, RPL18A, EDN1, CTSS, MRP63, EIF5, RPS3, RPL18, MMP1 (includes EG:4312), RPL13, SRC, RRBPI, PJA1, EIF3H, RPL3, RPL34, C9ORF3, RPS2, APAF1, CEBPB, DCTN2, RPS12, KIAA0368, RPL15, WARS, RPL28, USE1, SGSM3, IFT52, SMURF2, PLAU	44
Cell Death	1.78E-04 to 3.06E-02	LIF, ATXN1, NME2, CDKN2C, TMEML32A, ARG2, MSX2, RBPI, PTEN, SOD2, CASP9, CCNB1IPI, CTSS, PQBPI, SUB1, NUPRI, FOSL2, BIRC3, HLA-C, FBL, NOX4, RP5-886K2.1, NOVA1, YWHAE, SGCG, MITF, FGFR1, THRA, JUNB, NFKB2, NDN, ADI1, OGG1, CCND2, RAPGEF2, BTG2, PRKACA, RUNX1, CYLD, LRIG1, MME, BRD2, GABPB2, ICAM1, RGS3, MMP14, KLF10, BMP2, SAT1, EXT1, DUSP22, TNFAIP3, FKBP1A, FN1A, NFKBI, QARS, ASNS, RPLP0 (includes EG:6175), COMP, EIF4EBPI, PGF, RASSF1, ANGPTL4, NFKBIA, EDN1, FOXO3, ACTC1, MMP1 (includes EG:4312), ATN1, B4GALT5, MUC1, CALR, SRC, PXN, PRMT2, THG1L, PPIF, BGN, ELL, APAF1, PPP1R15A (includes EG:23645), CEBPB, CLCF1, IGF2R, PRG2 (includes EG:5553), NUP62, MAFB, CTH, PLAU, ATP2B4	90
Cellular Development	2.14E-04 to 3.06E-02	LIF, NME2, SFPO, MSX2, EEFD, LIMK1, PTEN, SERPINB2, NR4A3, CDON, POSTN, NUPRI, FOSL2, NOX4, NABI, MITF, FGFR1, THRA, LICAM, NFKB2, MBD2, JUNB, NDN, CCND2, BTG2, RUNX1, MAST2, MSC, ICAM1, NLGN1, MMP14, BMP2, KLF10, MCC, METTL8, TNFAIP3, EXT1, NFKBI, PGF, RASSF1, NFKBIA, EDN1, FOXO3, ATN1, MMP1 (includes EG:4312), SRC, NHEJ1, CALR, PXN, RELB, ELL, APAF1, IRAK3, CEBPB, IGF2R, CLCF1, AFF1, RBPJ, MAFB, PLAU	60
Lipid Metabolism	2.41E-04 to 3.06E-02	MUC1, SRC, CASP9, EDN1, APAF1, PHGDH, FAR2, ABCA1, PTEN	9
Molecular Transport	2.41E-04 to 3.06E-02	CACNA1G, CALR, SRC, YWHAE, ATXN1, NUP133, SAT1, APAF1, NUP50, ABCA1, CASP9, EDN1, SMG7, PHGDH, ATP2B4	15

*Fischer's exact test was used to calculate a p-value determining the probability that each biological function assigned to that data set is due to chance alone.

Table 4: Ingenuity Pathways Analysis: Top Bio Functions - Diseases and Disorders

Category	P-value*	Molecules	N°
Cancer	1.12E-04 to 3.06E-02	RPL22, EPS8, LIF, NME2, SFPQ, CDKN2C, SSH1, PTEN, LIMK1, SERPINB2, SOD2, CASP9, CTSS, POSTN, NEDD4L, BIRC3, EPB41L1, CACNA1G, SOX4, YWHAE, RRAD, FGFR1, L1CAM, MBD2, NFKB2, JUNB, SIPI, AD11, OGG1, NDN, CCND2, RAPGEF2, BTG2, PRKACA, RUNX1, CYLD, LRIG1, MME, BRD2, ICAMI, GEM, RGS3, BMP2, KLF10, MMP14, MCC, HAX1, SAT1, FKBPIA, EXT1, SEPT9, NFKB1, RPLP0 (includes EG:6175), COMP, EIF4EBP1, PGF, RASSF1, NFKBIA, ANGPTL4, EDN1, FOXO3, TAOK2 (includes EG:9344), MEG3 (includes EG:55384), B4GALT5, MMP1 (includes EG:4312), MUC1, CALR, SRC, PXN, RELB, APAF1, PPP1R15A (includes EG:23645), CEBPB, CLCF1, IGF2R, AFF1, NOV, PLAU	78
Hematological Disease	1.12E-04 to 3.06E-02	LIF, ICAMI, MCC, SFPQ, NFKB1, SERPINB2, PTEN, EIF4EBP1, CASP9, NFKBIA, HLA-C, SRC, RELB, ELL, MAN2A1, NFKB2, JUNB, CEBPB, CLCF1, AFF1, CCND2, BTG2, PRKACA, CYLD, PLAU, RUNX1, LRIG1	27
Immunological Disease	1.12E-04 to 3.06E-02	ICAMI, LIF, BGN, MMP14, BMP2, RELB, CDKN2C, NFKB2, JUNB, NFKB1, RPLP0 (includes EG:6175), CLCF1, PTEN, SOD2, CASP9, CCND2, NFKBIA, BTG2, FOXO3, RUNX1, CYLD, LRIG1, BIRC3, HLA-C	24
Renal and Urological Disease	3.57E-04 to 3.06E-02	SRC, RASSF1, SOD2, EDN1, POSTN, NUPRI, PLAU, LRIG1, SIPI, PTEN	10
Skeletal and Muscular Disorders	6.71E-04 to 3.06E-02	MME, LIF, ICAMI, BMP2, MMP14, EXT1, TNFAIP3, C18ORF10, IDE, NFKB1, PTEN, NR4A3, CASP9, SOD2, NFKBIA, EDN1, CTSS, FOXO3, RPS3, MAPKAPK2, MMP1 (includes EG:4312), HLA-C, SRC, NOX4, PPIF, MITF, BGN, APAF1, L1CAM, NFKB2, CEBPB, NDN, DCTN2, CLIC2, NUP62, PLAU, RUNX1, ATP2B4, C20ORF43, MCTP2	40

*Fischer's exact test was used to calculate a p-value determining the probability that each biological function and/or disease assigned to that data set is due to chance alone.

types also display molecular alterations. Lymphocytes from patients show reduced proliferation and impaired translational rates irrespective of the nature of the mutation [22]. An abnormal proliferation rate has been found also in fibroblasts from patients with mutations in *RPS19*. Additionally, both lymphocytes and fibroblasts are characterised by impaired pre-rRNA processing with accumulation of 21S species. Fibroblasts show abnormal nucleoli, which have irregular shape and disorganised dense fibrillar centers, the compartments where early pre-ribosome maturation takes place [11].

To characterise the molecular abnormalities in DBA non-haematopoietic cells, we evaluated gene expression profiles of fibroblasts isolated from DBA patients carrying mutations in *RPS19*. Patients 1 and 2 carried mutations leading to amino acid substitutions (p.Arg62Trp and p.Arg101His), the mutation in patient 3 (c.1-1G>A) impairs the correct splicing of the first intron and abrogates the ATG start codon, whereas the mutation in patient 4 (c.del58G) causes a frameshift of the open reading frame with insertion of a premature stop codon. Regardless of the heterogeneity of the mutational types, we did not observe any significant difference when mis-sense cases were compared to the other mutations, although this may be due to the limited number of patient samples of each mutational class in our study.

Gene expression profiling has been previously performed on bone marrow CD34⁺ cells isolated from three DBA patients with mutations in *RPS19* and in remission from the disease (i.e. without any treatment for at least 10 years), compared with healthy controls [23], and on CD4⁺ peripheral blood mononuclear cells from two DBA patients with unknown mutations compared with two acquired aplastic anaemia patients [24]. Our study demonstrates for the first time a global alteration of several biological processes in non-haematopoietic DBA cells. In agreement with previous studies [23,24], we identified a cluster of 22 ribosomal protein genes down-regulated in DBA patients relative to controls. Patients exhibit significant down-regulation of genes encoding proteins important for translation, including several eukaryotic translation initiation factors (*EIF3*, *EIF2*, *EIF4E*), *EIF3* and *EIF4* interacting proteins (*EIF3S6IP* and *EIF4EBP1*) and the eukaryotic elongation factor 1 δ (*EEF1D*). This may be caused either by the co-regulated transcription of RP genes or by their coordinated post-transcriptional regulation.

Most interestingly, among down-regulated genes we identified a large cluster of aminoacyl-tRNA synthetases (*QARS*, *EPRS*, *SARS*, *GARS*, *LARS*, *WARS*). Aminoacyl-tRNA synthetases (*ARS*) catalyse the aminoacylation of their cognate tRNAs and thus are key enzymes to maintain the fidelity of protein synthesis. In mammals, additional

Table 5: Ingenuity Pathways Analysis: Top Bio Functions - Physiological System Development and Function

Category	P-value*	Molecules	N°
Connective Tissue Development and Function	2.14E-04 to 3.06E-02	RPL22, ICAMI, LIF, KLF10, BMP2, MMP14, METTL8, HAX1, TNFAIP3, NFKB1, MSX2, EIF4EBP1, PTEN, PGF, LIMK1, EDN1, CHST3, FOSL2, SSBP3, MMP1 (includes EG:4312), SRC, PXN, MITF, BGN, JUNB, IRAK3, CEBPB, NFKB2, IGF2R, NDN, NOV, RUNX1, PLAU	33
Embryonic Development	2.14E-04 to 3.06E-02	LIF, ICAMI, BMP2, EXT1, NUP50, MSX2, PTEN, NR4A3, NFKBIA, RASSF1, EDN1, POSTN, FOSL2, SRC, PXN, MITF, FGFR1, THRA, LICAM, JUNB, CEBPB, AFF1, BTG2, RBPJ, IFT52, PLAU	26
Skeletal and Muscular System Development and Function	2.14E-04 to 3.06E-02	MSC, VAMP5, LIF, MMP14, BMP2, KLF10, METTL8, FKBP1A, EXT1, NFKB1, COMP, MSX2, PGF, PTEN, SATB2, NFKBIA, EDN1, CDON, FOXO3, CHST3, POSTN, FOSL2, ACTC1, SSBP3, CACNA1G, SRC, NOX4, BMP2K (includes EG:55589), NAB1, SGCG, MITF, FGFR1, BGN, ADCY3, THRA, NFKB2, IRAK3, JUNB, SMA4, RBPJ, PLAU, RUNX1	42
Tissue Morphology	2.14E-04 to 3.06E-02	ICAMI, LIF, BMP2, NFKB1, MSX2, ABCA1, PGF, PTEN, EIF4EBP1, CASP9, NFKBIA, EDN1, CTSS, PHGDH, FOSL2, SSBP3, SRC, RELB, BGN, ZICI, APAF1, LICAM, THRA, JUNB, NFKB2, CEBPB, OGG1, AFF1, CCND2, RBPJ, CYLD, PLAU, ATP2B4	33
Respiratory System Development and Function	1.44E-03 to 3.06E-02	SRC, NFKBIA, CCND2, COX11, EDN1, MAN2A1, MAFB, ABCA1, NDN, PTEN	10

*Fischer's exact test was used to calculate a p-value determining the probability that each biological function assigned to that data set is due to chance alone.

cofactors, i.e. proteins p18, p38 and p43, and interacting core proteins are required to form a functional multisynthetase complex [25]. The gene encoding p18 (*CDKN2C*) is also down-regulated in DBA fibroblasts. Moreover, ARS contribute to the regulation of amino acid metabolism, which is tightly regulated and essential for ribosome biogenesis and function. Human tryptophanyl-tRNA synthetase (*WARS*) is up-regulated after IFN-gamma treatment, together with indoleamine 2,3-dioxygenase (*IDO*), the enzyme responsible for tryptophan degradation, thus creating a pool of Trp-tRNA and providing a reservoir of Trp available for protein synthesis [26-28]. Interestingly, haem stimulates Trp catabolism enhancing both *IDO* and *WARS* enzymatic activities [29,30]. An abnormal haem catabolism has been suggested to occur in DBA [31]. Finally, non canonical functions have been proposed for glutamyl-prolyl-tRNA synthetase (*EPRS*) in the translational regulation of specific genes containing a GAIT element in the 3'UTR [32]. We demonstrate here that these key regulators are defective in fibroblasts from DBA patients. This suggests that a differential regulation of specific mRNAs may have a role in DBA.

High levels of erythrocyte adenosine deaminase (*eADA*) activity are a common clinical feature in DBA patients, suggesting that adenine catabolism is stimulated. This

most likely happens since DBA cells show the impaired processing of rRNA precursor species, which markedly accumulate in the nucleoli and need to be degraded [14]. Interestingly, we observed an increased expression of adenosine monophosphate deaminase (*AMPD3*), an enzyme of nucleotide break-down involved in the regulation of energetic metabolism in mammalian cells. It catalyses the irreversible deamination of adenylic acid and represents a branchpoint of adenylate nucleotides catabolism, regulating the size of the purine nucleotide pool [33,34]. The maintenance of an appropriate intracellular purine nucleotide concentration range is necessary for cell survival. The increased expression of *AMPD3* may indicate the need to dispose of an excess purine pool in DBA fibroblasts.

About 4% of DBA patients develop cancer, most frequently acute myeloid leukemia, myelodysplastic syndrome and osteosarcoma [5]. This prevalence is much higher than that in the general population. Thus DBA patients seem to have an increased risk of developing malignancies. Gene expression analysis performed on fibroblasts from DBA patients revealed dysregulation of genes involved in cell death and cancer. The decrease in pro-apoptotic (*CASP9*, *APAF1*) and oncosuppressor genes (*PTEN*), coupled to the increased expression of some




Figure 2
Gene expression by qRT-PCR. a) The mean relative expression in the group of DBA patients relative to the group of controls (set equal to 1) is reported for each analysed gene. Beta actin was used to normalise data. P values less than 0.05 were considered as statistically significant. b) Correlation of fold changes in the expression of analysed genes by microarray and qRT-PCR. The R^2 coefficient of correlation is reported. c) The mean relative expression in the group of DBA patients relative to the group of controls is reported for each analysed gene. Fold changes obtained from qRT-PCR and microarray analysis are shown for each analysed gene.

oncogenes (*SRC*, *CYLD*) and pro-survival genes (*CALR*) may suggest a predisposition for *RPS19* mutated fibroblasts to carcinogenesis. It is interesting to note that several zebrafish lines carrying heterozygous mutations for RP genes are also prone to develop malignancies [35].

Finally, patient fibroblasts differentially express several genes involved in embryonic and tissue development, including *ZIC1*, strongly down-regulated in patients. In mice, deletion of *zic1* gene results in cerebellar malformations and axial skeletal abnormalities [36,37]. It is worthwhile stressing that 30-48% of DBA patients display congenital malformations, including abnormalities affecting the skeletal axis, such as preaxial polydactyly.

Conclusion

The global gene expression analysis we performed shed light for the first time on the impaired biological processes in a non-haematopoietic cell type in DBA. We revealed a dysregulation of genes involved in ribosome biogenesis and protein synthesis, as well as amino acid and nucleotide metabolism. These data support the hypothesis that DBA may be due to a defect in general or specific protein synthesis.

Methods

Patients and cell culture

This study was performed on four DBA patients, carrying two missense (p.Arg62Trp and p.Arg101His), one frameshift and a splice site mutations (c.58delG and c.1-1G>A), respectively, in *RPS19*. Table 1 reports the main clinical characteristics of these patients. Further information about these mutations and their functional characterisation may be found in [4] and in the DBA genes Database [38,39].

Research was carried out in compliance with the Helsinki Declaration. Dermal biopsies were obtained from the four DBA patients and from six healthy controls after informed consent during surgery for medical reasons that were not connected with this study. Fibroblasts were cultured in IMDM (Iscove's Modified Dulbecco's Medium) supplemented with 4 mM L-glutamine, 10% foetal calf serum, 0.1 mg/ml streptomycin, 100 U/ml penicillin (Sigma-Aldrich) at 37°C and 5% CO₂. Total RNA was extracted from 10⁶ cells upon reaching 80% confluence, within 2-5 tissue culture passages.

RNA isolation, microarray processing and data analysis

Total RNA was isolated using the TRIzol reagent (Invitrogen) according to manufacturer's instructions, and purified with the RNeasy Mini kit (QIAGEN). The quality of total RNA was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies). RNA was quantified with a NanoDrop 1000 spectrophotometer (Thermo Scientific). A 6 µg-amount of each total RNA sample was labelled according to the standard one-cycle amplification and labelling protocol developed by Affymetrix (Santa Clara, CA). Labelled cRNA was hybridised on Affymetrix GeneChip Human Genome U133A 2.0 Arrays containing over 18,000 transcripts. Hybridized arrays were stained and washed (GeneChip Fluidics Station 450) and then




Figure 3
Comparison between qRT-PCR and microarray fold changes. The relative expression of genes analysed by qRT-PCR is reported for each sample. The mean expression of controls was used as calibrator (set equal to 1) and beta actin was used to normalise data. Fold changes obtained from microarray analysis are shown for each analysed gene.

scanned (GeneChip Scanner 3000 7G). Cell intensity values and probe detection calls were computed from the raw array data using the Affymetrix GeneChip Operating Software (GCOS). Further data processing was performed in the R computing environment [40] using packages from the BioConductor software project [41]. Robust Multi-Array Average (RMA) normalisation was applied [42]. Normalised data were then filtered based on the Affymetrix detection call, so that only probes that had a Present call in at least one of the arrays were retained [43]. Probes with low intensity values (less than 100) in all arrays were also excluded from statistical analysis. Data were then imported into the MultiExperiment Viewer (MeV) software [44], and statistical analysis was performed with the SAM (Significance Analysis of Microarrays) module [45], implemented as in [46]. A False Discovery Rate (FDR) of 3% was applied to detect significantly differentially expressed genes in DBA patients versus healthy controls. Functional analysis of differentially expressed genes was performed through the use of Ingenuity Pathways Analysis [19]. Microarray data have been deposited in the NCBI Gene Expression Omnibus (GEO) database with Accession Number GSE14335.

Validation of data by real time RT-PCR

Genes to be validated were selected on the basis of potential interest and as representative of a wide range of expression fold changes in patients relative to controls. 500 ng of total RNA was reverse transcribed to cDNA using the High Capacity cDNA Archive Kit (Applied Biosystems) and random primers. Quantitative PCR was performed with an AbiPrism7000 instrument (Applied Biosystems) and 1 µl of cDNA was used in a 25-µl final volume reaction containing Power SYBR® Green PCR Master Mix (Applied Biosystems) and specific primers (see additional file 4: Primers used in the expression analysis by qRT-PCR). cDNA from each sample was examined in triplicate in each experiment. Experimental Ct values were normalised to beta actin, used as endogenous control. Gene expression was calculated in each sample relative to the mean of controls, using the formula 2^{-ddCt} , where dCt is $Ct_{gene} - Ct_{endo}$ and $ddCt$ is $dCt_{sample} - \text{mean } dCt_{controls}$. Differences in gene expression of patients relative to controls were statistically evaluated by *t* test for independent samples.

Mutation analysis

DBA patient 3 was further analyzed for exon 2 skipping in *RPS19* transcript. The coding sequence spanning exon 1 and exon 4 was PCR-amplified by standard procedures. PCR products were excised from agarose gel, purified with HiYield Gel/PCR DNA Fragments Extraction Kit (Real Biotech, Banqiao City, Taiwan) and sequenced in both directions using a Big Dye Terminator® v1.1 cycle sequencing kit (Applied Biosystems) and an Abi PRISM® 3100 genetic

analyzer (Applied Biosystems). Primer sequences are available upon request.

Authors' contributions

FA performed qRT-PCR analysis, gene clustering analysis, mutation analysis and drafted the manuscript. PR performed bioinformatic and statistical microarray data analysis, participated in the interpretation of the data and critically revised the manuscript. NC and CC isolated and cultured fibroblasts. HK carried out microarray hybridisations. EG and MFC genotyped the patients and carried out RNA isolation. MA participated in gene clustering analysis. UR was involved in diagnosis and follow-up of patients, provided their samples and clinical information. SG, CS and ID contributed to the conception and design of the study, interpretation of the data and critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Additional material

Additional file 1

Genes differentially expressed in DBA patients identified by microarray profiling. The table reports the probeset IDs which are differentially expressed in DBA patients relative to controls, with an FDR of 3%. The gene annotation, chromosome location and fold change of expression in patients relative to controls is also reported.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2164-10-442-S1.pdf>]

Additional file 2

Differentially expressed genes in females relative to males. The table reports the probeset IDs which are differentially expressed in females relative to males, with an FDR of 10%. The gene annotation, chromosome location and fold change of expression in females relative to males is also reported.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2164-10-442-S2.pdf>]

Additional file 3

Differentially expressed genes in female patients relative to male patients. The table reports the probeset IDs which are differentially expressed in female DBA patients relative to male DBA patients, with an FDR of 10%. The gene annotation, chromosome location and fold change of expression in females relative to males is also reported.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2164-10-442-S3.pdf>]

Additional file 4

Primers used in the expression analysis by qRT-PCR. The table reports the sequence of both forward and reverse primers used to amplify genes in the validation experiments by qRT-PCR. The final concentration used in the reactions is also indicated for each primer.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2164-10-442-S4.pdf>]

Acknowledgements

This work was funded from grants from the Diamond Blackfan Anemia Foundation (to I.D.), Telethon (to I.D.), PRIN 2006 (to I.D. and U.R.), Regione Piemonte Ricerca Sanitaria Finalizzata (to U.R.) and Compagnia San Paolo (to IRCAD). We thank Andrew Bradbury for the revision of the manuscript and helpful discussion. We also thank the Daniella Maria Arturi Foundation for supporting communication among DBA researchers.

References

- Lecompte O, Ripp R, Thierry JC, Moras D, Poch O: **Comparative analysis of ribosomal proteins in complete genomes: an example of reductive evolution at the domain scale.** *Nucleic Acids Res* 2002, **30**:5382-5390.
- Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR, Golub TR: **Identification of RPS14 as a 5q-syndrome gene by RNA interference screen.** *Nature* 2008, **451**:335-9.
- Liu JM, Ellis SR: **Ribosomes and marrow failure: coincidental association or molecular paradigm?** *Blood* 2006, **107**:4583-4588.
- Campagnoli MF, Ramenghi U, Armiraglio M, Quarello P, Garelli E, Carando A, Avondo F, Pavesi E, Fribourg S, Gleizes PE, Loreni F, Dianzani I: **RPS19 mutations in patients with Diamond-Blackfan anemia.** *Hum Mutat* 2008, **7**:911-920.
- Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U, Meerpohl J, Karlsson S, Liu JM, Leblanc T, Paley C, Kang EM, Leder EJ, Atsidaftos E, Shimamura A, Bessler M, Glader B, Lipton JM, Participants of Sixth Annual Daniella Maria Arturi International Consensus Conference: **Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference.** *Br J Haematol* 2008, **142**:859-876.
- Cmejla R, Cmejlova J, Handrkova H, Petrak J, Pospisilova D: **Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia.** *Hum Mutat* 2007, **28**:1178-82.
- Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, Dianzani I, Ball S, Tchernia G, Klar J, Matsson H, Tentler D, Mohandas N, Carlsson B, Dahl N: **The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia.** *Nat Genet* 1999, **21**:169-75.
- Farrar JE, Nater M, Caywood E, McDevitt MA, Kowalski J, Takemoto CM, Talbot CC Jr, Meltzer P, Esposito D, Beggs AH, Schneider HE, Grabowska A, Ball SE, Niewiadomska E, Sieff CA, Vlachos A, Atsidaftos E, Ellis SR, Lipton JM, Gazda HT, Arceci RJ: **Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia.** *Blood* 2008, **112**:1582-1592.
- Gazda HT, Grabowska A, Merida-Long LB, Latawiec E, Schneider HE, Lipton JM, Vlachos A, Atsidaftos E, Ball SE, Orfali KA, Niewiadomska E, Da Costa L, Tchernia G, Niemeyer C, Meerpohl JJ, Stahl J, Schrott G, Glader B, Backer K, Wong C, Nathan DG, Beggs AH, Sieff CA: **Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia.** *Am J Hum Genet* 2006, **79**:1110-1108.
- Gazda HT, Sheen MR, Vlachos A, Choessel V, O'Donohue MF, Schneider H, Darras N, Hasman C, Sieff CA, Newburger PE, Ball SE, Niewiadomska E, Matysiak M, Zaucha JM, Glader B, Niemeyer C, Meerpohl JJ, Atsidaftos E, Lipton JM, Gleizes PE, Beggs AH: **Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in diamond-blackfan anemia patients.** *Am J Hum Genet* 2008, **83**:769-780.
- Choessel V, Bacqueville D, Rouquette J, Noaillic-Depyre J, Fribourg S, Cretien A, Leblanc T, Tchernia G, Da Costa L, Gleizes PE: **Impaired ribosome biogenesis in Diamond-Blackfan anemia.** *Blood* 2007, **109**:1275-1283.
- Flygare J, Aspesi A, Bailey JC, Miyake K, Caffrey JM, Karlsson S, Ellis S: **Human RPS19, the gene mutated in Diamond Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits.** *Blood* 2007, **109**:980-986.
- Idol RA, Robledo S, Du HY, Crimmins DL, Wilson DB, Ladenson JH, Bessler M, Mason PJ: **Cells depleted for RPS19, a protein associated with Diamond Blackfan Anemia, show defects in 18S ribosomal RNA synthesis and small ribosomal subunit production.** *Blood Cells Mol Dis* 2007, **39**:35-43.
- Léger-Silvestre I, Caffrey JM, Dawaliby R, Alvarez-Arias DA, Gas N, Bertolone SJ, Gleizes PE, Ellis SR: **Specific Role for Yeast Homologs of the Diamond Blackfan Anemia-associated Rps19 Protein in Ribosome Synthesis.** *J Biol Chem* 2005, **280**:38177-38185.
- Robledo S, Idol RA, Crimmins DL, Ladenson JH, Mason PJ, Bessler M: **The role of human ribosomal proteins in the maturation of rRNA and ribosome production.** *RNA* 2008, **14**:1918-1929.
- Giri N, Kang E, Tisdale JF, Follman D, Rivera M, Schwartz GN, Kim S, Young NS, Rick ME, Dunbar CE: **Clinical and laboratory evidence for a trilineage haematopoietic defect in patients with refractory Diamond-Blackfan anaemia.** *Br J Haematol* 2000, **108**:167-175.
- Chatr-Aryamontri A, Angelini M, Garelli E, Tchernia G, Ramenghi U, Dianzani I, Loreni F: **Nonsense-mediated and nonstop decay of ribosomal protein S19 mRNA in Diamond-Blackfan anemia.** *Hum Mutat* 2004, **24**:526-533.
- Gazda HT, Zhong R, Long L, Niewiadomska E, Lipton JM, Ploszynska A, Zaucha JM, Vlachos A, Atsidaftos E, Viskochil DH, Niemeyer CM, Meerpohl JJ, Rokicka-Milewska R, Pospisilova D, Wiktor-Jedrzejczak W, Nathan DG, Beggs AH, Sieff CA: **RNA and protein evidence for haplo-insufficiency in Diamond-Blackfan anaemia patients with RPS19 mutations.** *Br J Haematol* 2004, **127**:105-113.
- Ingenuity Pathway Analysis Software [<http://www.ingenuity.com/>]
- Qin D, Wu H, Peng H, Yao Y, Ni Z, Li Z, Zhou C, Sun Q: **Heat stress-responsive transcriptome analysis in heat susceptible and tolerant wheat (*Triticum aestivum* L.) by using Wheat Genome Array.** *BMC Genomics* 2008 in press.
- Liu J, Huang Q, Higdon J, Liu W, Xie T, Yamashita T, Cheon K, Cheng C, Zuo J: **Distinct gene expression profiles and reduced JNK signaling in retinitis pigmentosa caused by RPI mutations.** *Hum Mol Genet* 2005, **14**:2945-2958.
- Cmejlova J, Dolezalova L, Pospisilova D, Petrylova K, Petrak J, Cmejla R: **Translational efficiency in patients with Diamond-Blackfan anemia.** *Haematologica* 2006, **91**:1456-1464.
- Gazda HT, Kho AT, Sanoudou D, Zaucha JM, Kohane IS, Sieff CA, Beggs AH: **Defective ribosomal protein gene expression alters transcription, translation, apoptosis, and oncogenic pathways in Diamond-Blackfan anemia.** *Stem Cells* 2006, **24**:2034-2044.
- Koga Y, Ohga S, Nomura A, Takada H, Hara T: **Reduced gene expression of clustered ribosomal proteins in Diamond-Blackfan anemia patients without RPS19 gene mutations.** *J Pediatr Hematol Oncol* 2006, **28**:355-361.
- Lee SW, Cho BH, Park SG, Kim S: **Aminoacyl-tRNA synthetase complexes: beyond translation.** *J Cell Sci* 2004, **117**:3725-3734.
- Shaw AC, Larsen MR, Roepstorff P, Justese J, Christiansen G, Birke-lund S: **Mapping and identification of interferon γ -regulates Hela cell proteins separated by immobilized pH gradient two-dimensional gel electrophoresis.** *Electrophoresis* 1999, **20**:984-993.
- Yasui H, Takai K, Yoshida R, Hayaishi O: **Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: Its possible occurrence in cancer patients.** *Proc Natl Acad Sci USA* 1986, **83**:6622-6626.
- Boasso A, Herbeval JP, Hardy AW, Winkler C, Shearer GM: **Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells.** *Blood* 2005, **105**:1574-1581.
- Wakasugi K: **Human tryptophanyl-tRNA synthetase binds with heme to enhance its aminoacylation activity.** *Biochemistry* 2007, **46**:11291-11298.
- Thomas SR, Salahifar H, Mashima R, Hunt NH, Richardson DR, Stocker R: **Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate.** *J Immunol* 2001, **166**:6332-6340.
- Rey MA, Duffy SP, Brown JK, Kennedy JA, Dick JE, Dror Y, Taylor CS: **Enhanced alternative splicing of the FLVCR1 gene in Diamond Blackfan anemia disrupts FLVCR1 expression and function that are critical for erythropoiesis.** *Haematologica* 2008, **93**:1617-26.
- Sampath P, Mazumder B, Seshadri V, Gerber CA, Chavatte L, Kinter M, Ting SM, Dignam JD, Kim S, Driscoll DM, Fox PL: **Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation.** *Cell* 2004, **119**:195-208.

33. Hunsucker SA, Mitchell BS, Spychala J: **The 5'-nucleotidases as regulators of nucleotide and drug metabolism.** *Pharmacol Ther* 2005, **107**:1-30.
34. Bianchi V, Spychala J: **Mammalian 5'-nucleotidases.** *J Biol Chem* 2003, **278**:46195-46198.
35. MacInnes AW, Amsterdam A, Whittaker CA, Hopkins N, Lees JA: **Loss of p53 synthesis in zebrafish tumors with ribosomal protein gene mutations.** *Proc Natl Acad Sci USA* 2008, **105**:10408-10413.
36. Aruga J, Minowa O, Yaginuma H, Kuno J, Nagai T, Noda T, Mikoshiba K: **Mouse Zic1 is involved in cerebellar development.** *J Neurosci* 1998, **18**:284-293.
37. Aruga J, Mizugishi K, Koseki H, Imai K, Balling R, Noda T, Mikoshiba K: **Zic1 regulates the patterning of vertebral arches in cooperation with Gli3.** *Mech Dev* 1999, **89**:141-150.
38. Boria I, Quarello P, Avondo F, Garelli E, Aspesi A, Carando A, Campagnoli MF, Dianzani I, Ramenghi U: **A new database for ribosomal protein genes which are mutated in Diamond-Blackfan Anemia.** *Hum Mutat* 2008, **29**:E263-270.
39. **Diamond-Blackfan anemia Leiden Open Variation Database** [<http://www.dbagenes.unibo.it/home.php>]
40. **The R Project for Statistical Computing** [<http://www.r-project.org/>]
41. **BioConductor open source software for bioinformatics** [<http://www.bioconductor.org/>]
42. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: **ummaries of Affymetrix GeneChip probe level data.** *Nucleic Acids Res* 2003, **31**:S15.
43. McClintick JN, Edenberg HJ: **Effects of filtering by Present call on analysis of microarray experiments.** *BMC Bioinformatics* 2006, **7**:49.
44. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J: **TM4: a free, open-source system for microarray data management and analysis.** *Biotechniques* 2003, **34**(2):374-378.
45. Tusher VG, Tibshirani R, Chu G: **Significance analysis of microarrays applied to the ionizing radiation response.** *Proc Natl Acad Sci USA* 2001, **98**:5116-5121.
46. Chu G, Narasimhan B, Tibshirani R, Tusher V: **SAM "Significance Analysis of Microarrays" Users Guide and Technical Document.** [<http://www-stat.stanford.edu/~tibs/SAM/>].

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

